Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board SHANGHAI, China and NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of...

Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board SHANGHAI, China and CUPERTINO, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders SHANGHAI, China and CUPERTINO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), clinical-stage biopharmaceutical firm engaged in the...

Cellular Biomedicine Group Announces Results of 2016 Annual General Meeting SHANGHAI, China and CUPERTINO, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...

Cellular Biomedicine Group Reports First Quarter 2016 Financial Results and Provides Business Highlights – Reported Positive Clinical Data from Phase IIb trial of ReJoin® haMPC therapy– Expanded Stem Cell Platform with the Launch of New Allogeneic Clinical Trial– Closed Strategic Investment of $43.13...